Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 190

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial

Catenacci, Daniel V T, Kang, Yoon-Koo, Park, Haeseong, Uronis, Hope E, Lee, Keun-Wook, Ng, Matthew C H, Enzinger, Peter C, Park, Se Hoon, Gold, Philip J, Lacy, Jill, Hochster, Howard S, Oh, Sang Cheul, Kim, Yeul Hong, Marrone, Kristen A, Kelly, Ronan J, Juergens, Rosalyn A, Kim, Jong Gwang, Bendell, Johanna C, Alcindor, Thierry, Sym, Sun Jin, Song, Eun-Kee, Chee, Cheng Ean, Chao, Yee, Kim, Sunnie, Lockhart, A Craig, Knutson, Keith L, Yen, Jennifer, Franovic, Aleksandra, Nordstrom, Jeffrey L, Li, Daner, Wigginton, Jon, Davidson-Moncada, Jan K, Rosales, Minori Koshiji, Bang, Yung-Jue · 2020 · The Lancet Oncology

Abstract

BACKGROUND Margetuximab, a novel, investigational, Fc-engineered, anti-HER2 monoclonal antibody, is designed to more effectively potentiate innate immunity than trastuzumab. We aimed to evaluate the safety, tolerability, and antitumour activity of margetuximab plus pembrolizumab (an anti-PD-1 monoclonal antibody) in previously treated patients with HER2-positive gastro-oesophageal adenocarcinoma. METHODS CP-MGAH22-05 was a single-arm, open-label, phase 1b-2 dose-escalation and cohort expansion study done at 11 academic centres in the USA and Canada and 15 centres in southeast Asia (Korea, Taiwan, and Singapore) that enrolled men and women aged 18 years or older with histologically proven, unresectable, locally advanced or metastatic, HER2-positive, PD-L1-unselected gastro-oesophageal adenocarcinoma, with an Eastern Cooperative Oncology Group performance status of 0 or 1, who had progressed after at least one previous line of therapy with trastuzumab plus chemotherapy in the locally advanced unresectable or metastatic setting. In the dose-escalation phase, nine patients were treated: three received margetuximab 10 mg/kg intravenously plus pembrolizumab 200 mg intravenously every 3 weeks and six received the recommended phase 2 dose of margetuximab 15 mg/kg plus pembrolizumab 200 mg intravenously every 3 weeks. An additional 86 patients were enrolled in the phase 2 cohort expansion and received the recommended phase 2 dose. The primary endpoints were safety and tolerability, assessed in the safety population (patients who received at least one dose of either margetuximab or pembrolizumab) and the objective response rate as assessed by the investigator according to both Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, in the response-evaluable population (patients with measurable disease at baseline and who received the recommended phase 2 dose of margetuximab and pembrolizumab). This trial is registered with ClinicalTrials.gov, NCT02689284. Recruitment for the trial has completed and follow-up is ongoing. FINDINGS Between Feb 11, 2016, and Oct 2, 2018, 95 patients were enrolled. Median follow-up was 19·9 months (IQR 10·7-23·1). The combination therapy showed acceptable safety and tolerability; there were no dose-limiting toxicities in the dose-escalation phase. The most common grade 3-4 treatment-related adverse events were anaemia (four [4%]) and infusion-related reactions (three [3%]). Serious treatment-related adverse events were reported in nine (9%) patients. No treatment-related deaths were reported. Objective responses were observed in 17 (18·48%; 95% CI 11·15-27·93) of 92 evaluable patients. INTERPRETATION These findings serve as proof of concept of synergistic antitumour activity with the combination of an Fc-optimised anti-HER2 agent (margetuximab) along with anti-PD-1 checkpoint blockade (pembrolizumab). FUNDING MacroGenics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(20)30326-0

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 190

Metadata

Authors
Catenacci, D. V. T., Kang, Y.-K., Park, H., Uronis, H. E., Lee, K.-W., Ng, M. C. H., Enzinger, P. C., Park, S. H., Gold, P. J., Lacy, J., Hochster, H. S., Oh, S. C., Kim, Y. H., Marrone, K. A., Kelly, R. J., Juergens, R. A., Kim, J. G., Bendell, J. C., Alcindor, T., Sym, S. J., Song, E.-K., Chee, C. E., Chao, Y., Kim, S., Lockhart, A. C., Knutson, K. L., Yen, J., Franovic, A., Nordstrom, J. L., Li, D., Wigginton, J., Davidson-Moncada, J. K., Rosales, M. K., & Bang, Y.-J.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2020-08
Volume
21
Issue
8
Pages
1066-1076
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3042132061
Cited by
190
References
2
FWCI
15.88
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30326-0
The paper
Catenacci, D. V. T., Kang, Y.-K., Park, H., Uronis, H. E., Lee, K.-W., Ng, M. C. H., Enzinger, P. C., Park, S. H., Gold, P. J., Lacy, J., Hochster, H. S., Oh, S. C., Kim, Y. H., Marrone, K. A., Kelly, R. J., Juergens, R. A., Kim, J. G., Bendell, J. C., Alcindor, T., . . . Bang, Y.-J. (2020). Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30326-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.